Evaluation of the correlation between the spectra of volatile organic compounds (VOCs), measured with GC-IMS and MOx sensors, and the venous blood glucose level in individuals with type 2 diabetes

Critères de participation
- Signed written informed consent T2D treated with one or more oral antidiabetic agents (including GLP-1 and/or GIP) - Less than 16 years since T2D diagnosis - HbA1c ≤ 8% (HbA1c based on the last measurement by the treating physician, but not older than 120 days) - Willingness to undergo all study procedures (sub-study 1-3) - Age 45 - 70 years (inclusive) (BASEC)

Critères d'exclusion
- Pregnancy and/or breastfeeding - Current chronic or occasional treatment with lung medications - Smoking (last cigarette within the last six months) - BMI over 35 kg/m² - Lp(a) over 125 nmol/l - LDL not within the individual target range of a previous cholesterol target according to ESC guidelines 2021 (LDL based on the last measurement by the treating physician, but not older than 30 days) - Irregular 12-lead ECG or increased arterial plaque burden, based on a three-point ultrasound. Both examinations are performed and assessed at the discretion of the investigator. - History or manifest cardiovascular disease - Medical history of epilepsy or other neurological disorders associated with seizure events - Known sensitivity to medical adhesives - Comorbidities that are likely to alter the VOC spectra - Participation in another investigation with an investigational drug within 30 days prior to and during the current investigation - Limited German or English language skills (BASEC)